This webinar covered
With recent technological advancements and the discovery of more associations between microbiome in the human body, the spectrum of infectious diseases targeted by microbiome therapies has expanded considerably. In our recent webinar, we explored this evolving landscape as a result of recent FDA approvals, the ongoing focuses on gastrointestinal infections, and other infections, and how this affects the top disease indications at the forefront for microbiome drug developers in the coming years.
Key aspects explored include:
- A comprehensive overview of the current drug space in targeting infectious diseases
- Insights into the developers within the infectious diseases space and analysis of the two most active sectors
- Emerging trends: What the clinically active landscape tells us about how the space will evolve